Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript

Core Viewpoint - Esperion Therapeutics has announced a definitive agreement to acquire Corstasis Therapeutics, which will enhance its cardiovascular franchise with the product Enbumyst [2][3]. Group 1: Acquisition Details - The acquisition involves an upfront cash payment of $75 million, along with royalties on worldwide sales of Enbumyst and potential milestone payments of up to $180 million [4]. Group 2: Product Information - Enbumyst is the first and only FDA-approved nasal spray loop diuretic specifically for treating edema associated with congestive heart failure [3]. - The acquisition is expected to leverage Esperion's established cardiovascular commercial infrastructure, thereby expanding its product portfolio and accelerating double-digit revenue growth [3].